Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYB005 RSV Vaccine in Older Adults
NCT07208461Phase 2Active, not recruiting
- Sponsor
- Patronus Biotech
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of LYB005 in respiratory syncytial virus infection (RSV), sponsored by Patronus Biotech. Started Oct 2025; status: active, not recruiting.
02
Drugs
LYB005
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07208461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208461.